On July 2, 2024, Bolt Biotherapeutics, Inc. was sued for violations of the federal securities laws in the United States District Court for the Northern District of California on behalf of investors who purchased or otherwise acquired Bolt securities between February 5, 2021 and May 14, 2024, both dates inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.